Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases

摘要

BackgroundProstate cancer is the most frequently diagnosed cancer in men in the United States. There is scant real-world evidence characterizing the care utilization and clinical outcomes associated with the use of therapies currently approved by the US Food and Drug Administration (FDA) for patients with metastatic castrate-resistant prostate cancer (CRPC).